Skip to main content

Table 1 Clinical information for the pre- and post-mTORi eras

From: Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility

 

pre-mTORi era

post-mTORi era

p-value

Age at SEGA removal operation (years)

6, 6-19 years, mean 10, median 8.5, SD 5.02

2, 1-9 years, mean 5, median 5, SD 5.65

0.407

Age at mTORi administration (years)

n/a

11, 0.8-24 years, mean 12.3, median 14, SD 8.17

n/a

Age at presentation to our hospital 

7, 9-41 years, mean 22.6, median 19, SD 11.3

17, 0.8-23 years, mean 10.5, median 12, SD 7.7

0.031*

Current age (years)

7, 19-43 years, mean 29.9, median 29, SD 8.78

17, 1-29 years, mean 14, median 15, SD 8.16

0.002*

Sex (male / female)

3 f / 4 m

5 f / 12 m

 
  1. mTORi Mammalian target of rapamycin inhibitor, n/a Not available, SD Standard deviation, SEGA Subependymal giant cell astrocytoma